<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="psp413205" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11494824</article-id><article-id pub-id-type="pmcid-ver">PMC11494824.1</article-id><article-id pub-id-type="pmcaid">11494824</article-id><article-id pub-id-type="pmcaiid">11494824</article-id><article-id pub-id-type="pmid">39039947</article-id><article-id pub-id-type="doi">10.1002/psp4.13205</article-id><article-id pub-id-type="publisher-id">PSP413205</article-id><article-id pub-id-type="other">PSP-2023-0242-T</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Population pharmacokinetic modeling of sufentanil in adult Korean patients undergoing cardiopulmonary bypass surgery</article-title><alt-title alt-title-type="right-running-head">PK model of sufentanil in patients undergoing CPB</alt-title><alt-title alt-title-type="left-running-head">Khaowroongrueng et&#160;al.</alt-title></title-group><contrib-group><contrib id="psp413205-cr-0001" contrib-type="author"><name name-style="western"><surname>Khaowroongrueng</surname><given-names initials="V">Vipada</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-8710-1284</contrib-id><xref rid="psp413205-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413205-cr-0002" contrib-type="author"><name name-style="western"><surname>Son</surname><given-names initials="KH">Kuk Hui</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0595-5645</contrib-id><xref rid="psp413205-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413205-cr-0003" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="SM">Sang&#8208;Min</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9386-1170</contrib-id><xref rid="psp413205-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="psp413205-cr-0004" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="J">JiYeon</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0327-371X</contrib-id><xref rid="psp413205-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="psp413205-cr-0005" contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="CG">Chun&#8208;Gon</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8269-5058</contrib-id><xref rid="psp413205-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="psp413205-cr-0006" contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="SI">Seok In</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8538-4511</contrib-id><xref rid="psp413205-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413205-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Shin</surname><given-names initials="D">Dongseong</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4227-374X</contrib-id><xref rid="psp413205-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>dsshin@gilhospital.com</email></address></contrib><contrib id="psp413205-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Shin</surname><given-names initials="KH">Kwang&#8208;Hee</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0915-2700</contrib-id><xref rid="psp413205-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>kshin@knu.ac.kr</email></address></contrib></contrib-group><aff id="psp413205-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Research and Development Institute</named-content>
<institution>The Government Pharmaceutical Organization</institution>
<city>Bangkok</city>
<country country="TH">Thailand</country>
</aff><aff id="psp413205-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Thoracic and Cardiovascular Surgery, Gil Medical Center, College of Medicine</named-content>
<institution>Gachon University</institution>
<city>Incheon</city>
<country country="KR">Korea</country>
</aff><aff id="psp413205-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">College of Pharmacy, Research Institute of Pharmaceutical Sciences</named-content>
<institution>Kyungpook National University</institution>
<city>Daegu</city>
<country country="KR">Korea</country>
</aff><aff id="psp413205-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Anesthesiology and Pain Medicine, Gil Medical Center, College of Medicine</named-content>
<institution>Gachon University</institution>
<city>Incheon</city>
<country country="KR">Korea</country>
</aff><aff id="psp413205-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Pharmacology and Therapeutics, Gil Medical Center, College of Medicine</named-content>
<institution>Gachon University</institution>
<city>Incheon</city>
<country country="KR">Korea</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Dongseong Shin, Department of Clinical Pharmacology and Therapeutics, Gil Medical Center, College of Medicine, Gachon University, Incheon 21565, Korea.<break/>
Email: <email>dsshin@gilhospital.com</email><break/>
Kwang&#8208;Hee Shin, College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea.<break/>
Email: <email>kshin@knu.ac.kr</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2024</year></pub-date><volume>13</volume><issue seq="80">10</issue><issue-id pub-id-type="pmc-issue-id">473236</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v13.10</issue-id><fpage>1682</fpage><lpage>1692</lpage><history><date date-type="rev-recd"><day>29</day><month>5</month><year>2024</year></date><date date-type="received"><day>28</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>09</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>23</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-23 10:25:38.123"><day>23</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-13-1682.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-13-1682.pdf"/><abstract><title>Abstract</title><p>Sufentanil is frequently used as an anesthetic agent in cardiac surgery owing to its cardiovascular safety and favorable pharmacokinetics. However, the pharmacokinetics profiles of sufentanil in patients undergoing cardiopulmonary bypass (CPB) surgery remain less understood, which is crucial for achieving the desired level of anesthesia and mitigating surgical complications. Therefore, this study aimed to develop a population pharmacokinetic model of sufentanil in patients undergoing CPB surgery and elucidate the clinical factors affecting its pharmacokinetic profile. Adult patients who underwent cardiac surgery with CPB and were administered sufentanil for anesthesia were enrolled. Arterial blood samples were collected to quantify plasma concentrations of sufentanil and clinical laboratory parameters, including inflammatory cytokines. A population pharmacokinetic model was established using nonlinear mixed&#8208;effects modeling. Simulations were performed using the pharmacokinetic parameters of the final model. Overall, 20 patients were included in the final analysis. Sufentanil pharmacokinetics were modeled using a two&#8208;compartment model, accounting for CPB effects. Sufentanil clearance increased 2.80&#8208;fold during CPB and warming phases, while the central compartment volume increased 2.74&#8208;fold during CPB. CPB was a significant covariate affecting drug clearance and distribution volume. No other significant covariates were identified despite increased levels of the inflammatory cytokines, including IL&#8208;6, IL&#8208;8, and TNF&#8208;&#945; during CPB. The simulation indicated a 30&#8201;&#956;g loading dose and 40&#8201;&#956;g/h maintenance infusion for target&#8208;controlled infusion. Additionally, a bolus dose of 60&#8201;&#956;g was added at CPB initiation to adjust for exposure changes during this phase. Considering the target sufentanil concentrations, a uniform dosing regimen was acceptable for effective analgesia.</p></abstract><abstract abstract-type="graphical"><p>This study developed a population pharmacokinetic model of sufentanil in patients undergoing CPB, revealing that CPB significantly affects drug clearance and distribution, leading to recommendations for adjusted dosing regimens during surgery.<boxed-text position="anchor" content-type="graphic" id="psp413205-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-13-1682-g003.jpg"/></boxed-text>
</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Research Foundation of Korea
</institution><institution-id institution-id-type="doi">10.13039/501100003725</institution-id></institution-wrap></funding-source><award-id>2022K2A9A1A09092375</award-id><award-id>2020R1F1A1072586</award-id><award-id>RS&#8208;2023&#8208;00251397</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="11"/><word-count count="5700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.9 mode:remove_FC converted:22.10.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PSP413205-cit-2001"><string-name name-style="western"><surname>Khaowroongrueng</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Son</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S&#8208;M</given-names></string-name>, et al. <article-title>Population pharmacokinetic modeling of sufentanil in adult Korean patients undergoing cardiopulmonary bypass surgery</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2024</year>;<volume>13</volume>:<fpage>1682</fpage>&#8208;<lpage>1692</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.13205</pub-id><pub-id pub-id-type="pmcid">PMC11494824</pub-id><pub-id pub-id-type="pmid">39039947</pub-id></mixed-citation>
</p><fn-group id="psp413205-ntgp-0001"><fn id="psp413205-note-0001"><p>Vipada Khaowroongrueng and Kuk Hui Son contributed equally.</p></fn></fn-group></notes></front><body id="psp413205-body-0001"><p>
<boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="psp413205-list-0001"><list-item id="psp413205-li-0001"><p>
<bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>Various factors could affect drug pharmacokinetics in patients undergoing surgery with cardiopulmonary bypass (CPB). However, the pharmacokinetics of sufentanil in these patients remain improperly characterized.
<list list-type="simple" id="psp413205-list-0002"><list-item id="psp413205-li-0002"><p>
<bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>This study aimed to develop a population pharmacokinetic model for sufentanil in adult patients undergoing CPB and identify the clinical factors affecting its pharmacokinetic profiles.
<list list-type="simple" id="psp413205-list-0003"><list-item id="psp413205-li-0003"><p>
<bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>This study introduces the CPB&#8208;adjusted model for sufentanil. Based on the availability of covariate information, a standardized dosing regimen for sufentanil is proposed for patients undergoing cardiac surgery with CPB support.
<list list-type="simple" id="psp413205-list-0004"><list-item id="psp413205-li-0004"><p>
<bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
</p></list-item></list>
</p><p>By elucidating the effect of CPB on the pharmacokinetics of sufentanil, our findings can impact opioid management during cardiac surgery.</p></boxed-text>
</p><sec id="psp413205-sec-0003"><title>INTRODUCTION</title><p>Sufentanil, an opioid commonly used to induce anesthesia in cardiac surgery, is known for its cardiovascular safety and favorable pharmacokinetic profile.<xref rid="psp413205-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> It undergoes rapid distribution and has a short elimination half&#8208;life. Metabolized primarily in the liver via CYP3A4 enzymes, genetic polymorphisms of these enzymes can influence drug exposure.<xref rid="psp413205-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="psp413205-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Target&#8208;controlled infusion (TCI) of opioids was introduced to achieve intraoperative hemodynamic stability and reduce opioid requirement; however, its effectiveness is dependent on the pharmacokinetic parameters.<xref rid="psp413205-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="psp413205-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> However, during cardiac surgery, patient conditions and surgical procedures can alter the pharmacokinetics of anesthetic agents.<xref rid="psp413205-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="psp413205-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Therefore, ensuring the accuracy and applicability of pharmacokinetic parameters are crucial for achieving the desired level of anesthesia and minimizing surgical complications.</p><p>Cardiopulmonary bypass (CPB) is an extracorporeal circulation circuit utilized to temporarily support heart&#8208;lung functions during cardiac surgery. Physiological changes occurring during the CPB can significantly affect drug pharmacokinetics. Factors such as blood pressure regulation or hypothermia can influence regional blood flow, intracellular pH, and intrinsic metabolic enzyme activities, thereby affecting the distribution and elimination of sufentanil.<xref rid="psp413205-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="psp413205-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> CPB circuit priming causes acute hemodilution, resulting in reduced drug concentration.<xref rid="psp413205-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Moreover, the discontinuation of lung circulation during CPB may considerably affect the distribution of sufentanil, which is sequestered in the lungs.<xref rid="psp413205-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Additionally, various factors, including blood contact with the CPB circuit components, ischemia&#8211;reperfusion injury, heparin&#8211;protamine interactions, and surgical trauma, can activate the inflammatory cascade, leading to inflammatory cytokine release.<xref rid="psp413205-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="psp413205-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Increased levels of these cytokines are associated with adverse clinical outcomes and alteration in drug metabolism.<xref rid="psp413205-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp413205-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="psp413205-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Given the effect of inflammatory cytokines, changes in sufentanil exposures in relation to CPB operation was assessed.</p><p>The key limitations of pharmacokinetic studies in CPB surgery include small sample sizes, operational risks, and complexity. Nevertheless, establishing a rational dosing regimen grounded in pharmacokinetic evidence for patients undergoing cardiac surgery with CPB support holds significant clinical importance. Therefore, this study aims to investigate the development of a population pharmacokinetic model for sufentanil and the identification of clinical factors influencing its pharmacokinetics. The ultimate goal is to propose a rational regimen for CPB&#8208;supported surgery.</p></sec><sec sec-type="methods" id="psp413205-sec-0004"><title>METHODS</title><sec id="psp413205-sec-0005"><title>Study design and ethics approval</title><p>This prospective pharmacokinetic study was conducted at the Department of Thoracic and Cardiovascular Surgery, Gachon University Gil Medical Center, Incheon, South Korea, between May 2021 and June 2022. The study protocol received approval from the Institutional Review Board of the Gachon University Gil Medical Center (GDIRB 2021&#8208;184). The study was registered at the Clinical Research Information Service (CRIS, KCT0008742). Prior to enrollment, written informed consent was obtained from all participants. The study adhered to the principles outlined in the Declaration of Helsinki and its subsequent amendments, and the International Conference on Harmonization Guidelines for Good Clinical Practice.</p></sec><sec id="psp413205-sec-0006"><title>Study participants</title><p>Patients aged &gt;19&#8201;years who underwent cardiac surgery with CPB support and received sufentanil were included in the study. Patients undergoing renal replacement therapy or taking medications known to interact with sufentanil were excluded. Table&#160;<xref rid="psp413205-tbl-0001" ref-type="table">1</xref> presents the demographic and clinical characteristics of the 22 participants.</p><table-wrap position="float" id="psp413205-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic data and relevant clinical information of the study subjects.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">Number/Median (range), <italic toggle="yes">n</italic>&#8201;=&#8201;22</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male/female)</td><td align="left" valign="top" rowspan="1" colspan="1">14/8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (year)</td><td align="left" valign="top" rowspan="1" colspan="1">66 (23&#8211;77)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height (cm)</td><td align="left" valign="top" rowspan="1" colspan="1">169.2 (150.1&#8211;189.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">66.4 (46.7&#8211;99.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">23.9 (16.0&#8211;34.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CYP3A4*1G genotype (GG/GA/AA)</td><td align="left" valign="top" rowspan="1" colspan="1">13/6/3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total IV bolus dose (&#956;g/kg)</td><td align="left" valign="top" rowspan="1" colspan="1">2.3 (1.5&#8211;3.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total IV infusion dose (&#956;g/kg)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (0.9&#8211;4.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CPB duration (h)</td><td align="left" valign="top" rowspan="1" colspan="1">2.3 (1.4&#8211;5.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Surgical duration (h)</td><td align="left" valign="top" rowspan="1" colspan="1">7.7 (5.3&#8211;14.8)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Type of surgery</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Valvuloplasty or replacements</td><td align="left" valign="top" rowspan="1" colspan="1">13</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Coronary artery bypass graft</td><td align="left" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Left ventricular assist device</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Combination surgery</td><td align="left" valign="top" rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot id="psp413205-ntgp-0002"><fn id="psp413205-note-0002"><p>Abbreviation: CPB, cardiopulmonary bypass.</p></fn></table-wrap-foot></table-wrap></sec><sec id="psp413205-sec-0007"><title>
<styled-content style="fixed-case" toggle="no">CPB</styled-content> system</title><p>All patients underwent cardiac surgery with CPB utilizing an S5 roller pump (Sorin Stockert S5, Sorin Group, Muchen, Germany). Two types of membrane oxygenators were employed: the CAPIOX&#174; RX15 Oxygenator (Terumo Corporation, Tokyo, Japan) and Affinity NT (Medtronic Inc., Australasia, Australia). The CPB circuit was primed with 1700&#8201;mL of Plasma Solution A (inno.N, Cheongju, Korea), 100&#8201;mL of 20% albumin (GC, Yongin&#8208;si, Korea), 2000&#8201;units of heparin, and 40&#8201;mEq of bicarbonate. CPB was performed under mild hypothermia (core temperature&#8201;&gt;&#8201;32&#176;C), &#945;&#8208;stat pH management, and non&#8208;pulsatile flow during aortic cross&#8208;clamping. All patients were rewarmed to a rectal temperature of &#8805;36&#176;C before they were separated from CPB.</p></sec><sec id="psp413205-sec-0008"><title>Drug administration</title><p>Sufentanil was administered via the internal jugular vein. An intravenous (IV) bolus dose of 1&#8201;&#956;g/kg (Generally 50&#8201;&#956;g) was administered at intubation time. For anesthesia induction, 5&#8201;mg of midazolam (or 50&#8211;100&#8201;mg of propofol) and 0.8&#8211;1.0&#8201;mg/kg of rocuronium were coadministered intravenously. The anesthesia was sustained using sevoflurane (1&#8211;2&#8201;vol.%). Two additional bolus doses of 50&#8201;&#956;g were administered, specifically at the onset of CPB and rewarming phase. A continuous infusion was maintained at the rate of 20&#8201;&#956;g/h between the incision and CPB commencement and between CPB rewarming and conclusion of the procedure. The dosage was adjusted based on the condition of the patient, particularly considering factors such as the bispectral index or blood pressure. Other concomitant medications were administered at the discretion of the anesthesiologist.</p></sec><sec id="psp413205-sec-0009"><title>Study sample handling</title><p>Blood samples for the pharmacokinetic study were collected at specific intervals: pre&#8208;dose (0&#8201;h); 1&#8201;h after the first dose; pre&#8208;CPB initiation; 1&#8201;h after CPB commencement; and 1, 2, and 3&#8201;h following sufentanil cessation. Sufentanil concentration was determined using a validated liquid chromatography&#8211;tandem mass spectroscopy (LC&#8211;MS/MS) method.<xref rid="psp413205-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>Blood samples for assessing clinical laboratory parameters were collected at three specific timepoints: before dosing (0&#8201;h), pre&#8208;CPB initiation, and 1&#8201;h after CPB commencement. Changes in laboratory parameters and cytokine levels across these timepoints were analyzed using a mixed&#8208;effect model. The values were log&#8208;transformed owing to their non&#8208;normal distribution. Values falling below the lower limit of quantification (LLOQ) were adjusted to LLOQ/2 before log transformation.</p><p>The CYP3A4*1G genotype (rs2242480) was determined from blood samples using polymerase chain reaction (PCR) (Roche, Basel, Switzerland).<xref rid="psp413205-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> The study participants were classified as wild&#8208;type homozygote (CYP3A4*1/*1, GG), mutant heterozygote (CYP3A4*1/*1G, GA), or mutant homozygote (CYP3A4*1G/*1G, AA).</p><p>The detailed methods are provided in the <xref rid="psp413205-supitem-0001" ref-type="supplementary-material">Supplementary Material</xref>.</p></sec><sec id="psp413205-sec-0010"><title>Population pharmacokinetic modeling</title><p>Population pharmacokinetic models were constructed using NONMEM (version 7.5; Icon Development Solutions, Ellicott City, MD, USA). Typical population pharmacokinetic parameters, interindividual variability (IIV), and residual variability (RSV) were estimated using a first&#8208;order conditional estimation method with interaction. The models were executed and evaluated using Perl&#8208;speaks&#8208;NONMEM (PsN version 5.3.0)<xref rid="psp413205-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> and Xpose/R (version 3.4.4).<xref rid="psp413205-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> The models were constructed using Pirana (version 21.11.1).<xref rid="psp413205-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p></sec><sec id="psp413205-sec-0011"><title>Structural model</title><p>One&#8208;compartment (1&#8208;CMT), two&#8208;compartment (2&#8208;CMT), and three&#8208;compartment (3&#8208;CMT) compartment models with first&#8208;order elimination were fitted to the concentration&#8211;time data using NONMEM ADVAN subroutines. The pharmacokinetic models were parameterized regarding clearance (CL), compartment volume (V), and intercompartmental clearance (Q). A log&#8208;normal distribution was assumed for the IIV of the pharmacokinetic parameters. RSV was examined using additive, proportional, and combined residual errors model.</p></sec><sec id="psp413205-sec-0012"><title>
<styled-content style="fixed-case" toggle="no">CPB</styled-content>&#8208;adjusted model</title><p>CPB phases were recorded in the dataset as 0, 1, 2, and 3, denoting the pre&#8208;CPB, CPB, warming, and post&#8208;CPB phases, respectively. The pharmacokinetic parameters were considered to vary across the four CPB phases and were modeled as follows:<disp-formula id="psp413205-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>Pre</mml:mi><mml:mo linebreak="goodbreak">&#8208;</mml:mo><mml:mi>CPB</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413205-disp-0002"><label>(2)</label><mml:math id="jats-math-2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>CPB</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mi>CPB</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413205-disp-0003"><label>(3)</label><mml:math id="jats-math-3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Warming</mml:mtext><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mtext>warming</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413205-disp-0004"><label>(4)</label><mml:math id="jats-math-4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Post</mml:mtext><mml:mo linebreak="goodbreak">&#8208;</mml:mo><mml:mi>CPB</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mrow><mml:mtext>post</mml:mtext><mml:mo>&#8208;</mml:mo><mml:mi>CPB</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">P</italic>
<sub>
<italic toggle="yes">i,j</italic>
</sub> is the value of the <italic toggle="yes">j</italic>th model parameter for the <italic toggle="yes">i</italic>th individual; <italic toggle="yes">P</italic>
<sub>pop,<italic toggle="yes">j</italic>
</sub> denotes the typical value of the <italic toggle="yes">j</italic>th model parameter; <italic toggle="yes">&#951;</italic>
<sub>
<italic toggle="yes">i,j</italic>
</sub> represents the interindividual random effect for the <italic toggle="yes">i</italic>th individual of the <italic toggle="yes">j</italic>th parameter, assuming <italic toggle="yes">&#951;</italic>
<sub>
<italic toggle="yes">i,j</italic>
</sub> is ~<italic toggle="yes">N</italic>(0, <italic toggle="yes">&#969;</italic>
<sup>2</sup>); COV<sub>CPB</sub>, COV<sub>warming</sub>, and COV<sub>post&#8208;CPB</sub> are typical values of the covariate effect during the CPB, warming, and post&#8208;CPB phases, respectively.</p></sec><sec id="psp413205-sec-0013"><title>Covariate model</title><p>Potential covariates, including age, height, weight, body mass index, sex, CYP3A4*1G polymorphism, and fluid replacement volumes, which exhibited significant trends identified by plotting the random effects of the pharmacokinetic parameters (<italic toggle="yes">&#951;</italic>) against the covariates, were investigated in the model. Additionally, clinical laboratory parameters and inflammatory cytokines that demonstrated significant changes during CPB were explored in the model. A stepwise covariate model (comprising forward inclusion and backward elimination) was used to identify potential covariates. During the forward inclusion phase, all significant covariates&#8212;resulting in a reduction in the objective function value (OFV) of at least 3.84 (<italic toggle="yes">&#967;</italic>
<sup>2</sup> distribution, degrees of freedom [df]&#8201;=&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05)&#8212;were integrated into the full model. Subsequently, only covariates that led to an increase in the OFV of at least 6.63 (<italic toggle="yes">&#967;</italic>
<sup>2</sup> distribution, df&#8201;=&#8201;1, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) after backward elimination were retained in the final model.<xref rid="psp413205-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="psp413205-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The covariates were included in the models as follows:<disp-formula id="psp413205-disp-0005"><label>(5)</label><mml:math id="jats-math-5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Categorical covariates</mml:mtext><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413205-disp-0006"><label>(6)</label><mml:math id="jats-math-6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mtext>Continuous covariates</mml:mtext><mml:mo>:</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="13em"/><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>COV</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mi>med</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mrow><mml:mtext>COVpop</mml:mtext><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413205-disp-0007"><label>(7)</label><mml:math id="jats-math-7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mfenced close="]" open="["><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>COV</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8211;</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mi>med</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413205-disp-0008"><label>(8)</label><mml:math id="jats-math-8" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mi>exp</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mfenced close="]" open="["><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mrow><mml:mi>pop</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>COV</mml:mi><mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8211;</mml:mo><mml:msub><mml:mi>COV</mml:mi><mml:mrow><mml:mi>med</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>where COV<sub>pop,<italic toggle="yes">j</italic>
</sub> represents the typical value of the covariate effect of the <italic toggle="yes">j</italic>th model parameter; COV<sub>
<italic toggle="yes">i</italic>
</sub> denotes the covariate for the <italic toggle="yes">i</italic>th individual; COV<sub>med</sub> is the median of the covariate or reference value; COV(<italic toggle="yes">t</italic>)<sub>
<italic toggle="yes">i</italic>
</sub> represents the time&#8208;varying covariate for the <italic toggle="yes">i</italic>th individual; and COV<sub>med,<italic toggle="yes">i</italic>
</sub> is the median of the covariate for the <italic toggle="yes">i</italic>th individual.</p><p>Model selection was based on successful minimization, a significant reduction in OFV, visual inspection of goodness&#8208;of&#8208;fit (GOF) plots, individual pharmacokinetic profiles, precision of parameter estimates, density and distribution of IIV, decrease in IIV and RSV, and plausibility of the estimated parameters.</p></sec><sec id="psp413205-sec-0014"><title>Model diagnostics and validation</title><p>A bootstrap analysis comprising 1000 iterations was conducted to assess the reliability and stability of the estimated parameters in the final model.<xref rid="psp413205-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The capacity of the final model to describe concentration&#8211;time data was evaluated utilizing a prediction&#8208;corrected visual predictive check (pc&#8208;VPC, <italic toggle="yes">n</italic>&#8201;=&#8201;1000).<xref rid="psp413205-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The dependent variable values of the original dataset were compared to the prediction&#8208;corrected values of simulated datasets, depicted alongside the 95% confidence intervals (CIs) of the simulated 5th, 50th, and 95th percentile curves. The final model underwent validation using normalized prediction distribution error (NPDE), with 1000 simulations performed to generate the corresponding NPDE values, indicating the fit of each observation.<xref rid="psp413205-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p></sec><sec id="psp413205-sec-0015"><title>Simulations</title><p>Using the final model, a stochastic simulation of total plasma concentration was conducted with 1000 replicates. The IIV and RSV were fixed to the estimated values of the model. We assumed sufentanil was administered via TCI, and no difference in pharmacokinetics was observed between intermittent and continuous infusion. In the simulation dataset, the duration of cardiac surgery was presumed to be 7.5&#8201;h, encompassing 1.5&#8201;h of CPB and a 1&#8208;h warming phase. CPB was assumed to commence 2.5&#8201;h after the first dose of sufentanil, and the surgery was completed within 2.5&#8201;h following CPB weaning. The concentration&#8211;time profiles of sufentanil were simulated for 10&#8201;h. In the simulation dataset, doses of sufentanil were varied to propose a loading dose (25&#8211;40&#8201;&#956;g) and an additional IV bolus dose (50&#8211;80&#8201;&#956;g) corresponding to a target concentration of at least 0.5&#8211;0.7&#8201;ng/mL for pre&#8208;CPB control,<xref rid="psp413205-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> and an infusion rate (30&#8211;45&#8201;&#956;g/h) corresponding to a target concentration of 0.3&#8211;0.6&#8201;ng/mL for adequate anesthesia.<xref rid="psp413205-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> The total infusion time was adjusted from 5 to 6.5&#8201;h, considering that achieving a target concentration of approximately 0.15&#8201;ng/mL by the end of surgery has been demonstrated to facilitate spontaneous ventilation.<xref rid="psp413205-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p></sec></sec><sec sec-type="results" id="psp413205-sec-0016"><title>RESULTS</title><sec id="psp413205-sec-0017"><title>Subject characteristics</title><p>Males constituted a higher proportion of the study population (64%) than females. Regarding CYP3A4*1G polymorphisms, 13 participants were included in the GG group, 6 in the GA group, and 3in the AA group. The predominant surgical procedure was valvuloplasty or replacement (59%), followed by coronary artery bypass grafting (27%).</p></sec><sec id="psp413205-sec-0018"><title>Structural model</title><p>Overall, 110 samples were collected from 22 participants during the surgical procedures. However, two participants with 12 observations were excluded owing to significantly high pre&#8208;dose sufentanil concentrations. While the dose and time records were generally well captured, two outlier samples were suspected to be due to sampling error and were, therefore, omitted from the analysis. Therefore, the final dataset was derived from 20 participants with 96 observations. The concentration&#8211;time data for sufentanil were best described by a two&#8208;compartment model with first&#8208;order elimination. Individual concentration&#8211;time data were explored alongside dosing and CPB timing. A notable discrepancy between observed and predicted concentrations was noted during CPB (Figure&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S1</xref>). The IIV regarding CL was estimated. The proportional error was selected based on the decrease in the OFV (Model M2, Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="psp413205-sec-0019"><title>
<styled-content style="fixed-case" toggle="no">CPB</styled-content>&#8208;adjusted model</title><p>The effect of the CPB on CL, volume of the central compartment (V1), Q, and volume of the peripheral compartment (V2) was evaluated, permitting change across CPB phases (Equations&#160;<xref rid="psp413205-disp-0001" ref-type="disp-formula">(1)</xref>, <xref rid="psp413205-disp-0002" ref-type="disp-formula">(2)</xref>, <xref rid="psp413205-disp-0003" ref-type="disp-formula">(3)</xref>, <xref rid="psp413205-disp-0004" ref-type="disp-formula">(4)</xref>). The effect of CPB on CL during CPB and warming phases exhibited similarity; therefore, the CPB effect in these phases was estimated using the same typical value. Additionally, the effect of CPB on V1 during CPB was incorporated owing to a significant reduction in the OFV and improved GOF plots (Figure&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S2</xref>). The CPB&#8208;adjusted model estimated a 2.80&#8208;fold increase in CL during CPB and warming phases and a 2.74&#8208;fold increase in V1 during CPB (Model M11, Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S1</xref>). The effect of CPB on Q and V2 was not incorporated due to the considerably high relative standard error (RSE) of the parameter estimates.</p></sec><sec id="psp413205-sec-0020"><title>Clinical laboratory data and covariate model</title><p>Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S2</xref> shows the clinical laboratory data. Red blood cell counts, hematocrit, and levels of total protein, albumin, and creatinine measured 1&#8201;h post&#8208;CPB were lower than the respective pre&#8208;CPB values. Conversely, a significant increase was observed in IL&#8208;6, IL&#8208;8, and TNF&#8208;&#945; levels at 1&#8201;h post&#8208;CPB compared to the respective pre&#8208;CPB levels (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, respectively) (Figure&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S3</xref>). IL&#8208;1&#946; and IFN&#8208;&#947; levels exhibited no significant change, while the other cytokines remained below the LLOQ across various timepoints. Total protein and cytokines demonstrating a significant change during CPB were integrated into the model as time&#8208;varying covariates influencing CL. The inclusion of these variables did not result in any significant improvements in the model. Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S1</xref> summarizes our deliberations during model development. During the forward inclusion step, the effects of CPB on CL and V1 and the effect of sex on CL were included in the full model (Model M18, Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S1</xref>). However, only the effects of CPB on CL and V1 were retained in the final model following backward elimination (Model M11, Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="psp413205-sec-0021"><title>Model diagnostics and validation</title><p>Figure&#160;<xref rid="psp413205-fig-0001" ref-type="fig">1</xref> shows the GOF plots for the final model. A strong correlation was observed between the observed and predicted concentrations. The observations were dispersed around the unity line, with most conditional weighted residuals (CWRES) falling within &#177;2. The success rate in the 1000&#8208;bootstrap re&#8208;sampling procedure was 99%. The parameter estimates derived from the original dataset were comparable to the median values and fell within the 95% CIs obtained using the bootstrap method, underscoring the robustness of the final model (Table&#160;<xref rid="psp413205-tbl-0002" ref-type="table">2</xref>). The 95% CIs of the prediction&#8208;corrected concentrations in pc&#8208;VPC covered most of the corresponding observations, suggesting strong predictability across concentration&#8211;time profiles (Figure&#160;<xref rid="psp413205-fig-0002" ref-type="fig">2a</xref>). The mean NPDE was 0.05403 with a variance of 1.058 (globally adjusted <italic toggle="yes">p</italic>&#8201;=&#8201;1), suggesting a normal distribution of the simulated data (Figure&#160;<xref rid="psp413205-fig-0002" ref-type="fig">2b</xref>). The NPDE values were scattered around the zero line, with most of the data falling within &#177;2 (Figure&#160;<xref rid="psp413205-fig-0002" ref-type="fig">2c</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413205-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Goodness&#8208;of&#8208;fit plots. (a) Observed versus population predicted concentration; (b) Observed versus individual predicted concentration; (c) Conditional weighted residuals versus population predicted concentration; and (d) Conditional weighted residuals versus time.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-13-1682-g002.jpg"/></fig><table-wrap position="float" id="psp413205-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Pharmacokinetic parameters estimated from the final model.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Parameters</th><th align="left" colspan="3" valign="bottom" rowspan="1">Final model</th><th align="left" colspan="2" valign="bottom" rowspan="1">Bootstrap (<italic toggle="yes">n</italic>&#8201;=&#8201;1000)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Estimate</th><th align="left" valign="bottom" rowspan="1" colspan="1">RSE, %</th><th align="left" valign="bottom" rowspan="1" colspan="1">Shrinkage, %</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="6" valign="top" rowspan="1">Fixed effects</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CL (L/h)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">51.8</td><td align="left" valign="top" rowspan="1" colspan="1">16.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">50.8</td><td align="left" valign="top" rowspan="1" colspan="1">32.8&#8211;68.6</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">V1 (L)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">72.5</td><td align="left" valign="top" rowspan="1" colspan="1">12.1</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">72.1</td><td align="left" valign="top" rowspan="1" colspan="1">58.2&#8211;99.5</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Q (L/h)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">55.2</td><td align="left" valign="top" rowspan="1" colspan="1">17.2</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">58.8</td><td align="left" valign="top" rowspan="1" colspan="1">43.3&#8211;81.3</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">V2 (L)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">390</td><td align="left" valign="top" rowspan="1" colspan="1">43.8</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">420</td><td align="left" valign="top" rowspan="1" colspan="1">129&#8211;957</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CL <sub>CPB&amp;warming</sub>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.80</td><td align="left" valign="top" rowspan="1" colspan="1">14.4</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.78</td><td align="left" valign="top" rowspan="1" colspan="1">2.29&#8211;3.96</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">V1 <sub>CPB</sub>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.74</td><td align="left" valign="top" rowspan="1" colspan="1">18.5</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.80</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#8211;4.79</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Random effects</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIV CL (CV, %)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24.2</td><td align="left" valign="top" rowspan="1" colspan="1">22.4</td><td align="left" valign="top" rowspan="1" colspan="1">10.5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">23.2</td><td align="left" valign="top" rowspan="1" colspan="1">14.1&#8211;33.2</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIV V1 (CV, %)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">FIX</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">FIX</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIV Q (CV, %)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">FIX</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">FIX</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IIV V2 (CV, %)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">FIX</td><td align="left" valign="top" rowspan="1" colspan="1">&#8211;</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">FIX</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">RSV &#963;<sub>prop</sub> (%)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">25.3</td><td align="left" valign="top" rowspan="1" colspan="1">8.10</td><td align="left" valign="top" rowspan="1" colspan="1">7.20</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24.2</td><td align="left" valign="top" rowspan="1" colspan="1">20.8&#8211;27.6</td></tr></tbody></table><table-wrap-foot id="psp413205-ntgp-0003"><fn id="psp413205-note-0003"><p>Abbreviations: CL, clearance; IIV, interindividual variability; Q, intercompartmental clearance; RSE, relative standard error; RSV, residual variability; V, compartment volume.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="psp413205-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Predicted correlation visual predictive check (a) illustrating observed data (dots), the median (5%&#8211;95% percentile, solid lines), and respective 95% CIs (shaded area); and normalized prediction distribution errors (NDPE) illustrating NDPE distribution (b); and NPDE versus predicted concentration (c).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-13-1682-g001.jpg"/></fig></sec><sec id="psp413205-sec-0022"><title>Simulations</title><p>A simulation was performed to determine the suitable loading and maintenance doses of sufentanil. A loading dose of 30&#8201;&#956;g and a maintenance infusion rate of 40&#8201;&#956;g/h were recommended for TCI, considering the target concentrations at various CPB phases. Additionally, an extra IV bolus dose of 60&#8201;&#956;g was administered at CPB commencement to account for the hemodilution effect. The simulation indicated that the infusion could potentially be halted after 6&#8201;h, aligning with a target concentration of 0.15&#8201;ng/mL at the conclusion of the surgery. This assumption was based on the surgery being concluded within 1.5&#8201;h after sufentanil cessation (Figure&#160;<xref rid="psp413205-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413205-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Mean simulated concentration&#8211;time plot of sufentanil for the purposed dosing regimen of 30&#8201;&#956;g loading dose and 40&#8201;&#956;g/h maintenance infusion rate with an additional IV dose of 60&#8201;&#956;g at CPB initiation. Black dotted lines indicate a target concentration of 0.3&#8211;0.6&#8201;ng/mL for adequate anesthesia, while red dotted line indicates a target concentration of 0.15&#8201;ng/mL by the end of surgery.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PSP4-13-1682-g004.jpg"/></fig></sec></sec><sec sec-type="discussion" id="psp413205-sec-0023"><title>DISCUSSION</title><p>We opted for a two&#8208;compartment model with first&#8208;order elimination as the structural model. Typically, both two&#8208; and three&#8208;compartment models have been employed to characterize the pharmacokinetics of sufentanil following intravenous injection.<xref rid="psp413205-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> However, owing to the data availability, it was challenging to determine the triphasic decay in plasma concentration. Owing to the bias in the GOF and individual plots during CPB, the CPB&#8208;adjusted model was developed. CL exhibited an approximate 2.80&#8208;fold increase during the CPB and warming phases. While a decreased CL was anticipated during hypothermic CPB due to reduced hepatic blood flow,<xref rid="psp413205-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> mild hypothermia was employed in this study. Management of patients and CPB pump flow to maintain adequate tissue perfusion can result in increased hepatic CL during CPB compared to that in pre&#8208;CPB.<xref rid="psp413205-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Additionally, the increased CL can be attributed to the sequestration of opioids in CPB circuits, a phenomenon influenced by drug lipophilicity and dependent on the CPB component.<xref rid="psp413205-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="psp413205-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> An approximately 2.74&#8208;fold increase in V1 was estimated during CPB, which was anticipated due to hemodilution occurring shortly after CPB initiation.<xref rid="psp413205-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="psp413205-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="psp413205-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p><p>The parameters estimated in this study aligned closely with those previously reported for Caucasian populations. Nonetheless, different types of surgeries can influence drug distribution, as reflected by the volume of distribution (Vd) or the volume of distribution at the steady state (Vdss) (Table&#160;<xref rid="psp413205-supitem-0001" ref-type="supplementary-material">S3</xref>). No significant covariates were identified in these previous studies, which was consistent with our study findings. However, in a study of Korean patients undergoing extracorporeal membrane oxygenation (ECMO), body temperature and total plasma protein were observed to strongly affect the pharmacokinetics of sufentanil. In this study, the estimated Vd was larger in patients on ECMO support than in those on CPB support, potentially attributed to the differences between ECMO and CPB based on mechanical operations.<xref rid="psp413205-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Hudson et&#160;al. developed the CPB&#8208;adjusted model, in which V and Q changed during CPB or post&#8208;CPB.<xref rid="psp413205-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Conversely, Jeleazcov et&#160;al. revealed increased CL and Q with unaffected V during CPB.<xref rid="psp413205-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Variations in dosing schemes, concomitant drugs, sampling designs, and clinical settings can all contribute to the pharmacokinetic variability and alterations induced by extracorporeal circulation circuits.<xref rid="psp413205-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>Upon CPB implementation, some changes in the clinical laboratory parameters were observed. Specifically, red blood cell count, hematocrit, total protein, albumin, and creatinine levels during CPB were observed to be lower than their corresponding pre&#8208;CPB levels, potentially due to hemodilution. The reduced plasma protein levels may not affect the CL of sufentanil, as it is highly dependent on flow.<xref rid="psp413205-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Conversely, IL&#8208;6, IL&#8208;8, and TNF&#8208;&#945; levels increased during CPB and were consistent with patterns observed in previous studies.<xref rid="psp413205-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="psp413205-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> While certain inflammatory cytokines have been observed to exert an inhibitory effect on drug&#8208;metabolizing enzymes, none of these cytokines was identified as significant covariates in the pharmacokinetics model. This is likely because CYP inhibition is contingent on factors such as time or concentration.<xref rid="psp413205-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Similarly, the CYP3A4*1G polymorphism did not emerge as a significant covariate for sufentanil CL despite the anticipated decrease in CL in patients with the CYP3A4 mutant allele.<xref rid="psp413205-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The effects of these covariates may be elucidated by incorporating the CPB effect into the model. However, a larger dataset is warranted to comprehensively investigate the contributions of these covariates to the altered pharmacokinetics of sufentanil.</p><p>The recommended regimen of sufentanil for anesthetic management during cardiac surgery remains controversial, influenced by factors including intraoperative cardiovascular response and postoperative recovery. Presently, dosing adjustments are made based on the pathological state of the patient, combination medications, surgical procedure, and expertise of the anesthesiologist.<xref rid="psp413205-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp413205-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Using pharmacokinetic parameters obtained from patients undergoing general anesthesia for sufentanil TCI during cardiac surgery with CPB is not suitable.<xref rid="psp413205-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="psp413205-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="psp413205-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Therefore, we performed a simulation of sufentanil plasma concentration using the CPB&#8208;adjusted model with a modified dosing protocol. The therapeutic window of sufentanil in patients undergoing CPB remains undetermined. We utilized target concentrations of 0.3&#8211;0.6&#8201;ng/mL, as required for cardiac anesthesia in Korean patients undergoing ECMO.<xref rid="psp413205-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> However, these concentrations are comparable to values reported in other studies.<xref rid="psp413205-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="psp413205-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Maintaining sufentanil concentrations at pre&#8208;CPB is crucial for hemodynamic control in patients during cardiac surgery.<xref rid="psp413205-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Additionally, the concentration at the end of surgery is associated with postoperative complications, mechanical ventilation duration, and opioid consumption.<xref rid="psp413205-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="psp413205-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Therefore, characterizing pharmacokinetics in patients undergoing CPB could be valuable in guiding the TCI of sufentanil for anesthetic management during cardiac surgery.</p><p>This study had some limitations. First, the sample size was small, and the sampling interval was relatively short, limited to the duration of the surgical procedure. Moreover, detailed patient characteristics were lacking, representing key limitations. The small number of patients underwent various anesthesia conditions and surgical procedures, combined with their underlying health conditions, potentially affecting factors such as hemodilution, protein binding, and tissue distribution. Consequently, this could have affected the precision of the parameter estimates (&gt;30% RSE of V2). Additionally, it could limit the estimation of IIV for the pharmacokinetic parameters. Despite these limitations, the final model underwent evaluation using various approaches, confirming the reliability of the estimated pharmacokinetic parameters. Second, the sparse sampling design hindered the characterization of the temporal CPB effect during CPB initiation and weaning. Third, neither &#945;1&#8208;acid glycoprotein nor the unbound fraction of sufentanil was measured, precluding the investigation of the effect of CPB on unbound concentrations. The simulation was conducted to guide the dosing regimen based on the total concentration of sufentanil. However, the simulation was based on a model that incorporates uncertainties stemming from a limited number of participants. Therefore, caution is warranted when interpreting the performance of the CPB&#8208;adjusted model for TCI of sufentanil and its applicability to clinical settings, which should be confirmed in further clinical studies.</p><p>In conclusion, the objective of this study was achieved with the successful development of a population pharmacokinetic model of sufentanil in patients undergoing CPB. The CPB&#8208;adjusted model accurately characterized the plasma concentrations of sufentanil following intermittent administration. CPB significantly affected drug distribution and clearance. No covariates were found to account for the interindividual variability in pharmacokinetic parameters. Consequently, uniform dosing recommendations were proposed for this patient population, utilizing the available covariate information. Despite some limitations, the findings of this study shed light on the effect of CPB on the pharmacokinetics of sufentanil, potentially influencing opioid management strategies during cardiac surgery.</p></sec><sec id="psp413205-sec-0024"><title>AUTHOR CONTRIBUTIONS</title><p>V.K., K.H.S., D.S., and K.&#8208;H.S. wrote the manuscript; D.S. and K.&#8208;H.S. designed the research; V.K., K.H.S., S.&#8208;M.L., J.L., C.&#8208;G.P., and S.I.L. performed the research; V.K., J.L., C.P., and S.I.L. analyzed the data.</p></sec><sec id="psp413205-sec-0026"><title>FUNDING INFORMATION</title><p>This work was supported under the framework of international cooperation program managed by the National Research Foundation of Korea (NRF&#8208;2022K2A9A1A09092375). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. NRF&#8208;2020R1F1A1072586 and RS&#8208;2023&#8208;00251397).</p></sec><sec sec-type="COI-statement" id="psp413205-sec-0027"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declared no competing interests for this work.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp413205-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-13-1682-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="psp413205-sec-0025"><title>ACKNOWLEDGMENTS</title><p>The authors would like to acknowledge all the study participants, the study team, staff at Gil Medical Center for their practical support which was crucial to the successful completion of this study. The authors would also like to acknowledge Prof. Kwang&#8208;Hee Shin's group at Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University for assistance with the plasma concentration and genotype assays.</p></ack><sec sec-type="data-availability" id="psp413205-sec-0029"><title>DATA AVAILABILITY STATEMENT</title><p>The data presented in this study are available from the corresponding authors (Dr. Dongseong Shin, Dr. Kwang&#8208;Hee Shin) upon reasonable request.</p></sec><ref-list content-type="cited-references" id="psp413205-bibl-0001"><title>REFERENCES</title><ref id="psp413205-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="psp413205-cit-0001"><string-name name-style="western"><surname>Scholz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Steinfath</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>M</given-names></string-name>. <article-title>Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil</article-title>. <source>Clin Pharmacokinet</source>. <year>1996</year>;<volume>31</volume>:<fpage>275</fpage>&#8208;<lpage>292</lpage>.<pub-id pub-id-type="pmid">8896944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199631040-00004</pub-id></mixed-citation></ref><ref id="psp413205-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="psp413205-cit-0002"><string-name name-style="western"><surname>Monk</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Beresford</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>A</given-names></string-name>. <article-title>Sufentanil: a review of its pharmacological properties and therapeutic use</article-title>. <source>Drugs</source>. <year>1988</year>;<volume>36</volume>:<fpage>286</fpage>&#8208;<lpage>313</lpage>.<pub-id pub-id-type="pmid">2903821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003495-198836030-00003</pub-id></mixed-citation></ref><ref id="psp413205-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="psp413205-cit-0003"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>S</given-names></string-name>. <article-title>Patients with CYP3A4*1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection</article-title>. <source>Medicine (Baltimore)</source>. <year>2017</year>;<volume>96</volume>:<fpage>e6013</fpage>.<pub-id pub-id-type="pmid">28121959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000006013</pub-id><pub-id pub-id-type="pmcid">PMC5287983</pub-id></mixed-citation></ref><ref id="psp413205-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="psp413205-cit-0004"><string-name name-style="western"><surname>Schnider</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Minto</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Struys</surname><given-names>MMRF</given-names></string-name>, <string-name name-style="western"><surname>Absalom</surname><given-names>AR</given-names></string-name>. <article-title>The safety of target&#8208;controlled infusions</article-title>. <source>Anesth Analg</source>. <year>2016</year>;<volume>122</volume>:<fpage>79</fpage>&#8208;<lpage>85</lpage>.<pub-id pub-id-type="pmid">26516801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000001005</pub-id></mixed-citation></ref><ref id="psp413205-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="psp413205-cit-0005"><string-name name-style="western"><surname>Jeleazcov</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Saari</surname><given-names>TI</given-names></string-name>, <string-name name-style="western"><surname>Ihmsen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sch&#252;ttler</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fechner</surname><given-names>J</given-names></string-name>. <article-title>Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass</article-title>. <source>Br J Anaesth</source>. <year>2012</year>;<volume>109</volume>:<fpage>698</fpage>&#8208;<lpage>706</lpage>.<pub-id pub-id-type="pmid">22831891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/aes253</pub-id></mixed-citation></ref><ref id="psp413205-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp413205-cit-0006"><string-name name-style="western"><surname>Rodighiero</surname><given-names>V</given-names></string-name>. <article-title>Effects of cardiovascular disease on pharmacokinetics</article-title>. <source>Cardiovasc Drugs Ther</source>. <year>1989</year>;<volume>3</volume>:<fpage>711</fpage>&#8208;<lpage>730</lpage>.<pub-id pub-id-type="pmid">2577313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01857622</pub-id></mixed-citation></ref><ref id="psp413205-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp413205-cit-0007"><string-name name-style="western"><surname>Hall</surname><given-names>R</given-names></string-name>. <article-title>The pharmacokinetic behaviour of opioids administered during cardiac surgery</article-title>. <source>Can J Anaesth</source>. <year>1991</year>;<volume>38</volume>:<fpage>747</fpage>&#8208;<lpage>756</lpage>.<pub-id pub-id-type="pmid">1914058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03008453</pub-id></mixed-citation></ref><ref id="psp413205-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp413205-cit-0008"><string-name name-style="western"><surname>Holley</surname><given-names>FO</given-names></string-name>, <string-name name-style="western"><surname>Ponganis</surname><given-names>KV</given-names></string-name>, <string-name name-style="western"><surname>Stanski</surname><given-names>DR</given-names></string-name>. <article-title>Effect of cardiopulmonary bypass on the pharmacokinetics of drugs</article-title>. <source>Clin Pharmacokinet</source>. <year>1982</year>;<volume>7</volume>:<fpage>234</fpage>&#8208;<lpage>251</lpage>.<pub-id pub-id-type="pmid">7047043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-198207030-00004</pub-id></mixed-citation></ref><ref id="psp413205-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="psp413205-cit-0009"><string-name name-style="western"><surname>Barry</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Chaney</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>London</surname><given-names>MJ</given-names></string-name>. <article-title>Anesthetic management during cardiopulmonary bypass: a systematic review</article-title>. <source>Anesth Analg</source>. <year>2015</year>;<volume>120</volume>:<fpage>749</fpage>&#8208;<lpage>769</lpage>.<pub-id pub-id-type="pmid">25790208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000000612</pub-id></mixed-citation></ref><ref id="psp413205-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="psp413205-cit-0010"><string-name name-style="western"><surname>Okutani</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Philbin</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Rosow</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Koski</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>RC</given-names></string-name>. <article-title>Effect of hypothermic hemodilutional cardiopulmonary bypass on plasma sufentanil and catecholamine concentrations in humans</article-title>. <source>Anesth Analg</source>. <year>1988</year>;<volume>67</volume>:<fpage>667</fpage>&#8208;<lpage>670</lpage>.<pub-id pub-id-type="pmid">2968058</pub-id></mixed-citation></ref><ref id="psp413205-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="psp413205-cit-0011"><string-name name-style="western"><surname>Boer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Engbers</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Bovill</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Burm</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Hak</surname><given-names>A</given-names></string-name>. <article-title>First&#8208;pass pulmonary retention of sufentanil at three different background blood concentrations of the opioid</article-title>. <source>Br J Anaesth</source>. <year>1995</year>;<volume>74</volume>:<fpage>50</fpage>&#8208;<lpage>55</lpage>.<pub-id pub-id-type="pmid">7880706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bja/74.1.50</pub-id></mixed-citation></ref><ref id="psp413205-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="psp413205-cit-0012"><string-name name-style="western"><surname>Paparella</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yau</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>E</given-names></string-name>. <article-title>Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update</article-title>. <source>Eur J Cardiothorac Surg</source>. <year>2002</year>;<volume>21</volume>:<fpage>232</fpage>&#8208;<lpage>244</lpage>.<pub-id pub-id-type="pmid">11825729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1010-7940(01)01099-5</pub-id></mixed-citation></ref><ref id="psp413205-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="psp413205-cit-0013"><string-name name-style="western"><surname>Allan</surname><given-names>CK</given-names></string-name>, <string-name name-style="western"><surname>Newburger</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>McGrath</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass</article-title>. <source>Anesth Analg</source>. <year>2010</year>;<volume>111</volume>:<fpage>1244</fpage>&#8208;<lpage>1251</lpage>.<pub-id pub-id-type="pmid">20829561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0b013e3181f333aa</pub-id></mixed-citation></ref><ref id="psp413205-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp413205-cit-0014"><string-name name-style="western"><surname>Kraft</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Van Aken</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zarbock</surname><given-names>A</given-names></string-name>. <article-title>Inflammatory response and extracorporeal circulation</article-title>. <source>Best Pract Res Clin Anaesthesiol</source>. <year>2015</year>;<volume>29</volume>:<fpage>113</fpage>&#8208;<lpage>123</lpage>.<pub-id pub-id-type="pmid">26060024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpa.2015.03.001</pub-id></mixed-citation></ref><ref id="psp413205-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp413205-cit-0015"><string-name name-style="western"><surname>Gatti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pea</surname><given-names>F</given-names></string-name>. <article-title>The cytokine release syndrome and/or the proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and drug transport: a systematic review of the clinical pharmacokinetics of victim drugs of this drug&#8211;disease interaction under different clinical conditions</article-title>. <source>Clin Pharmacokinet</source>. <year>2022</year>;<volume>61</volume>:<fpage>1519</fpage>&#8208;<lpage>1544</lpage>.<pub-id pub-id-type="pmid">36059001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-022-01173-8</pub-id><pub-id pub-id-type="pmcid">PMC9441320</pub-id></mixed-citation></ref><ref id="psp413205-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="psp413205-cit-0016"><string-name name-style="western"><surname>Lee</surname><given-names>S&#8208;M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>K&#8208;H</given-names></string-name>. <article-title>Determination of sufentanil in human plasma using ultra&#8208;high performance liquid chromatography coupled with tandem mass spectrometry (UPLC&#8211;MS/MS)</article-title>. <source>Curr Anal Chem</source>. <year>2023</year>;<volume>19</volume>:<fpage>531</fpage>&#8208;<lpage>540</lpage>.</mixed-citation></ref><ref id="psp413205-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp413205-cit-0017"><string-name name-style="western"><surname>Ozeki</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nagahama</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fujita</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer</article-title>. <source>Sci Rep</source>. <year>2019</year>;<volume>9</volume>:<fpage>5404</fpage>.<pub-id pub-id-type="pmid">30931962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-41820-y</pub-id><pub-id pub-id-type="pmcid">PMC6443943</pub-id></mixed-citation></ref><ref id="psp413205-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp413205-cit-0018"><string-name name-style="western"><surname>Lindbom</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pihlgren</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jonsson</surname><given-names>N</given-names></string-name>. <article-title>PsN&#8208;toolkit&#8212;a collection of computer intensive statistical methods for non&#8208;linear mixed effect modeling using NONMEM</article-title>. <source>Comput Methods Programs Biomed</source>. <year>2005</year>;<volume>79</volume>:<fpage>241</fpage>&#8208;<lpage>257</lpage>.<pub-id pub-id-type="pmid">16023764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2005.04.005</pub-id></mixed-citation></ref><ref id="psp413205-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="psp413205-cit-0019"><string-name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></string-name>. <article-title>Xpose&#8212;an S&#8208;PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM</article-title>. <source>Comput Methods Programs Biomed</source>. <year>1998</year>;<volume>58</volume>:<fpage>51</fpage>&#8208;<lpage>64</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-2607(98)00067-4</pub-id><pub-id pub-id-type="pmid">10195646</pub-id></mixed-citation></ref><ref id="psp413205-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="psp413205-cit-0020"><string-name name-style="western"><surname>Keizer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>van Benten</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Schellens</surname><given-names>JHM</given-names></string-name>, <string-name name-style="western"><surname>Huitema</surname><given-names>ADR</given-names></string-name>. <article-title>Pira&#241;a and PCluster: a modeling environment and cluster infrastructure for NONMEM</article-title>. <source>Comput Methods Programs Biomed</source>. <year>2011</year>;<volume>101</volume>:<fpage>72</fpage>&#8208;<lpage>79</lpage>.<pub-id pub-id-type="pmid">20627442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2010.04.018</pub-id></mixed-citation></ref><ref id="psp413205-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="psp413205-cit-0021"><string-name name-style="western"><surname>Jonsson</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></string-name>. <article-title>Automated covariate model building within NONMEM</article-title>. <source>Pharm Res</source>. <year>1998</year>;<volume>15</volume>:<fpage>1463</fpage>&#8208;<lpage>1468</lpage>.<pub-id pub-id-type="pmid">9755901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1011970125687</pub-id></mixed-citation></ref><ref id="psp413205-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="psp413205-cit-0022"><string-name name-style="western"><surname>Ette</surname><given-names>EI</given-names></string-name>. <article-title>Stability and performance of a population pharmacokinetic model</article-title>. <source>J Clin Pharmacol</source>. <year>1997</year>;<volume>37</volume>:<fpage>486</fpage>&#8208;<lpage>495</lpage>.<pub-id pub-id-type="pmid">9208355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1997.tb04326.x</pub-id></mixed-citation></ref><ref id="psp413205-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="psp413205-cit-0023"><string-name name-style="western"><surname>Bergstrand</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hooker</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Wallin</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></string-name>. <article-title>Prediction&#8208;corrected visual predictive checks for diagnosing nonlinear mixed&#8208;effects models</article-title>. <source>AAPS J</source>. <year>2011</year>;<volume>13</volume>:<fpage>143</fpage>&#8208;<lpage>151</lpage>.<pub-id pub-id-type="pmid">21302010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-011-9255-z</pub-id><pub-id pub-id-type="pmcid">PMC3085712</pub-id></mixed-citation></ref><ref id="psp413205-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="psp413205-cit-0024"><string-name name-style="western"><surname>Comets</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Brendel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Mentr&#233;</surname><given-names>F</given-names></string-name>. <article-title>Computing normalised prediction distribution errors to evaluate nonlinear mixed&#8208;effect models: the npde add&#8208;on package for R</article-title>. <source>Comput Methods Programs Biomed</source>. <year>2008</year>;<volume>90</volume>:<fpage>154</fpage>&#8208;<lpage>166</lpage>.<pub-id pub-id-type="pmid">18215437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2007.12.002</pub-id></mixed-citation></ref><ref id="psp413205-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="psp413205-cit-0025"><string-name name-style="western"><surname>Hudson Robert</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Thomson Ian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jassal</surname><given-names>R</given-names></string-name>. <article-title>Effects of cardiopulmonary bypass on sufentanil pharmacokinetics in patients undergoing coronary artery bypass surgery</article-title>. <source>Anesthesiology</source>. <year>2004</year>;<volume>101</volume>:<fpage>862</fpage>&#8208;<lpage>871</lpage>.<pub-id pub-id-type="pmid">15448518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-200410000-00010</pub-id></mixed-citation></ref><ref id="psp413205-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp413205-cit-0026"><string-name name-style="western"><surname>Hahn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>KL</given-names></string-name>, et&#160;al. <article-title>Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy</article-title>. <source>Crit Care</source>. <year>2019</year>;<volume>23</volume>:<fpage>248</fpage>.<pub-id pub-id-type="pmid">31288863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-019-2508-4</pub-id><pub-id pub-id-type="pmcid">PMC6615282</pub-id></mixed-citation></ref><ref id="psp413205-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="psp413205-cit-0027"><string-name name-style="western"><surname>Sarkar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Prabhu</surname><given-names>V</given-names></string-name>. <article-title>Basics of cardiopulmonary bypass</article-title>. <source>Indian J Anaesth</source>. <year>2017</year>;<volume>61</volume>:<fpage>760</fpage>&#8208;<lpage>767</lpage>.<pub-id pub-id-type="pmid">28970635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ija.IJA_379_17</pub-id><pub-id pub-id-type="pmcid">PMC5613602</pub-id></mixed-citation></ref><ref id="psp413205-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="psp413205-cit-0028"><string-name name-style="western"><surname>Rosen</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Rosen</surname><given-names>KR</given-names></string-name>. <article-title>Elimination of drugs and toxins during cardiopulmonary bypass</article-title>. <source>J Cardiothorac Vasc Anesth</source>. <year>1997</year>;<volume>11</volume>:<fpage>337</fpage>&#8208;<lpage>340</lpage>.<pub-id pub-id-type="pmid">9161903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1053-0770(97)90104-x</pub-id></mixed-citation></ref><ref id="psp413205-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="psp413205-cit-0029"><string-name name-style="western"><surname>Durkan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lonergan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>N</given-names></string-name>. <article-title>Effect of membrane oxygenators on sufentanil blood levels during cardiopulmonary bypass</article-title>. <source>Anesth Analg</source>. <year>1988</year>;<volume>67</volume>:<fpage>54</fpage>.</mixed-citation></ref><ref id="psp413205-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="psp413205-cit-0030"><string-name name-style="western"><surname>Flezzani</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Alvis</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>JR</given-names></string-name>, et&#160;al. <article-title>Sufentanil disposition during cardiopulmonary bypass</article-title>. <source>Can J Anaesth</source>. <year>1987</year>;<volume>34</volume>:<fpage>566</fpage>&#8208;<lpage>569</lpage>.<pub-id pub-id-type="pmid">2960465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03010512</pub-id></mixed-citation></ref><ref id="psp413205-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="psp413205-cit-0031"><string-name name-style="western"><surname>Hirai</surname><given-names>S</given-names></string-name>. <article-title>Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass</article-title>. <source>Ann Thorac Cardiovasc Surg</source>. <year>2003</year>;<volume>9</volume>:<fpage>365</fpage>&#8208;<lpage>370</lpage>.<pub-id pub-id-type="pmid">15003097</pub-id></mixed-citation></ref><ref id="psp413205-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="psp413205-cit-0032"><collab collab-type="authors">Pfizer Medical Information</collab>
. <article-title>Highlights of prescribing information&#8208;sufentanil citrate injection, for intravenous and epidural use</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pfizermedicalinformation.com/sufentanil-citrate/highlights" ext-link-type="uri">https://www.pfizermedicalinformation.com/sufentanil&#8208;citrate/highlights</ext-link>. Accessed April 21, 2024.</mixed-citation></ref><ref id="psp413205-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="psp413205-cit-0033"><string-name name-style="western"><surname>Bailey</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Schwieger</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Hug</surname><given-names>CC</given-names><suffix>Jr</suffix></string-name>. <article-title>Evaluation of sufentanil anesthesia obtained by a computer&#8208;controlled infusion for cardiac surgery</article-title>. <source>Anesth Analg</source>. <year>1993</year>;<volume>76</volume>:<fpage>247</fpage>&#8208;<lpage>252</lpage>.<pub-id pub-id-type="pmid">8424499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/00000539-199302000-00008</pub-id></mixed-citation></ref><ref id="psp413205-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="psp413205-cit-0034"><string-name name-style="western"><surname>Barvais</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Heitz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schmartz</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Pharmacokinetic model&#8208;driven infusion of sufentanil and midazolam during cardiac surgery: assessment of the prospective predictive accuracy and the quality of anesthesia</article-title>. <source>J Cardiothorac Vasc Anesth</source>. <year>2000</year>;<volume>14</volume>:<fpage>402</fpage>&#8208;<lpage>408</lpage>.<pub-id pub-id-type="pmid">10972605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/jcan.2000.7931</pub-id></mixed-citation></ref><ref id="psp413205-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="psp413205-cit-0035"><string-name name-style="western"><surname>Bourgoin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alban&#232;se</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>L&#233;one</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sampol&#8208;Manos</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Viviand</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>C</given-names></string-name>. <article-title>Effects of sufentanil or ketamine administered in target&#8208;controlled infusion on the cerebral hemodynamics of severely brain&#8208;injured patients</article-title>. <source>Crit Care Med</source>. <year>2005</year>;<volume>33</volume>:<fpage>1109</fpage>&#8208;<lpage>1113</lpage>.<pub-id pub-id-type="pmid">15891344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ccm.0000162491.26292.98</pub-id></mixed-citation></ref><ref id="psp413205-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="psp413205-cit-0036"><string-name name-style="western"><surname>Fechner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ihmsen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sch&#252;ttler</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jeleazcov</surname><given-names>C</given-names></string-name>. <article-title>The impact of intra&#8208;operative sufentanil dosing on post&#8208;operative pain, hyperalgesia and morphine consumption after cardiac surgery</article-title>. <source>Eur J Pain</source>. <year>2013</year>;<volume>17</volume>:<fpage>562</fpage>&#8208;<lpage>570</lpage>.<pub-id pub-id-type="pmid">22927230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1532-2149.2012.00211.x</pub-id></mixed-citation></ref><ref id="psp413205-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="psp413205-cit-0037"><string-name name-style="western"><surname>Thomson Ian</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Henderson Blair</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hudson</surname><given-names>RJ</given-names></string-name>. <article-title>Concentration&#8208;response relationships for fentanyl and sufentanil in patients undergoing coronary artery bypass grafting</article-title>. <source>Anesthesiology</source>. <year>1998</year>;<volume>89</volume>:<fpage>852</fpage>&#8208;<lpage>861</lpage>.<pub-id pub-id-type="pmid">9778002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000542-199810000-00009</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>